20
Participants
Start Date
October 1, 2025
Primary Completion Date
August 1, 2026
Study Completion Date
August 1, 2027
Sulfur Hexafluoride Lipid Type A Microspheres 25 mg Injection Powder for Suspension [LUMASON]
Injection of Sulfur hexafluoride lipid-type A microspheres contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg before performing the contrast-enhanced ultrasound. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected.
RECRUITING
Children's Hospital of Philadelphia, Philadelphia
Children's Hospital of Philadelphia
OTHER